Byotrol PLC
01 November 2006
BYOTROL PLC
Placing to raise £5 million to accelerate growth
The Board of Byotrol plc (the 'Company') is pleased to announce that Charles
Stanley Securities has, on behalf of the Company, completed a placing (the
'Placing') of 8.34 million new Ordinary Shares of 0.25p each (the 'Placing
Shares') at 60 pence per share to raise approximately £4.6 million, net of
expenses.
The funds will be used by the Directors to address an increasing number of
opportunities that have been recently identified in the Company's target markets
of Healthcare, Food Processing and Industrial & Technical.
The Company recently obtained CE Marking status approving Byotrol for sale in
medical and disinfectant products in Europe and approval from the US Environment
Protection Agency for Byotrol to be used as a disinfectant, sanitiser and anti-
microbial product in a broad number of market sectors. As a result the Company
has been approached by several major multinationals interested in gaining access
to the Company's technology and the Company is currently engaged in discussions
with a number of these companies regarding the sale and/or licensing of Byotrol.
It is expected that the placing proceeds will assist the progress of such
discussions.
The Placing Shares will, when issued and fully paid, rank pari passu in all
respects with the existing issued ordinary shares of the Company.
The Placing is not a rights issue or open offer and the Placing Shares will not
be offered generally to Shareholders, whether on a pre-emptive basis or
otherwise. The Directors believe that the considerable extra cost and delay
involved in a rights issue or open offer would not be in the best interests of
the Company in the circumstances.
Richard Bell, a consultant to the Company, has acquired 10,000 Placing Shares,
pursuant to the Placing, and accordingly now owns 10,000 Ordinary Shares in the
Company.
Application has been made for the Placing Shares to be admitted to trading on
AIM and trading in the Placing Shares is expected to commence on Tuesday 7
November 2006. Following the admission of the Placing Shares to trading on AIM,
the Company will have 43,212,849 Ordinary Shares in issue.
Charles Stanley Securities has also placed a further 1,500,000 ordinary shares
on behalf of Mr Ragnar Olaffson, representing 4.30 per cent. of the current
issued share capital, with institutional investors at a price of 60p. Following
this, Mr Olaffson holds 1,298,000 ordinary shares, representing 3.72 per cent.
of the current issued share capital and 3.00 per cent. of the issued share
capital as enlarged by the Placing.
1 November 2006
Enquiries:
Byotrol plc 0161 277 9518
Stephen Falder
Deputy Chairman
David McRobbie
Chief Executive
Charles Stanley Securities 020 7149 6457
Philip Davies
First City PR 0207 436 7486
Allan Piper
McCann Erickson PR 01625 822540
Jim Rothnie
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.